Form SCHEDULE 13G Agomab Therapeutics NV Filed by: Sanofi

SCHEDULE 13G

CUSIP No.

1

Names of Reporting Persons

SANOFI

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

FRANCE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,783,096.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,783,096.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,783,096.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.71 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

Item 1.

(a)

Name of issuer:

AgomAb Therapeutics NV

(b)

Address of issuer's principal executive offices:

POSTHOFLEI 1/6, ANTWERPEN, Belgium, 2600

Item 2.

(a)

Name of person filing:

Sanofi

(b)

Address or principal business office or, if none, residence:

46, avenue de la Grande Armee, 75017 Paris, France

(c)

Citizenship:

The Republic of France

(d)

Title of class of securities:

Common Shares, no nominal value per share ("Common Shares")

(e)

CUSIP No.:

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k)

Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4.

Ownership

(a)

Amount beneficially owned:

There is no CUSIP number assigned to the Common Shares. CUSIP number 00860C102 has been assigned to the American Depositary Shares (ADSs) of the Issuer. Each ADS represents one Common Share. Sanofi directly holds 2,708,096 Common Shares and 75,000 ADSs, representing 75,000 Common Shares.

(b)

Percent of class:

5.71% %

(c)

Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

2,783,096 shares

(ii) Shared power to vote or to direct the vote:

0 shares

(iii) Sole power to dispose or to direct the disposition of:

2,783,096 shares

(iv) Shared power to dispose or to direct the disposition of:

0 shares

Item 5.

Ownership of 5 Percent or Less of a Class.

Item 6.

Ownership of more than 5 Percent on Behalf of Another Person.

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

Sanofi Foreign Participations B.V. 2,783,096 shares 5.71% *The shares are held of record by Sanofi Foreign Participations B.V., the reporting person's indirect, wholly owned subsidiaries.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

The response of the Reporting Person to Item 6 is incorporated herein by reference.

Item 8.

Identification and Classification of Members of the Group.

Not Applicable

Item 9.

Notice of Dissolution of Group.

Not Applicable

Item 10.

Certifications:

Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

SANOFI

Signature:	/s/ Alexandra Roger*
Name/Title:	Head of Legal Corporate & Finance
Date:	05/06/2025

Comments accompanying signature: *Alexandra Roger is signing on behalf of Sanofi by power of attorney previously filed with the Securities and Exchange Commission on February 3, 2016 as Exhibit 24 to Form 4, and hereby incorporated by reference herein.

Form SCHEDULE 13G Agomab Therapeutics NV Filed by: Sanofi

You May Also Be Interested In

Create E-mail Alert Related Categories

Related Entities

Sign up for StreetInsider Free!

Free News Feed